enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...

Related Keywords

Montreal ,Quebec ,Canada ,Boston ,Massachusetts ,United States ,Canadian ,Jason Hanson ,Derivatized Oligochitosan ,Lota Zoth ,Dgene Inc ,Forbion European Acquisition Corporation ,Exchange Commission ,Nasdaq ,Company Board Of Directors ,Company Annual Report On Form ,Company Audit Committee Chair ,Gene Holdings Inc ,Gene Holdings ,Chief Executive Officer ,Business Highlights ,Oversubscribed Private Placement ,Hercules Capital Debt Facility ,Leadership Hires ,Board Additions ,Succession Planning ,Ryan Daws ,Chief Financial Officer ,Lee Giguere ,Chief Legal Officer ,Audit Committee ,Bacillus Calmette Gu ,Dually Derivatized Oligochitosan ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Consolidated Statements ,